SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-266787
Filing Date
2020-10-09
Accepted
2020-10-09 08:01:02
Documents
14
Period of Report
2020-10-08
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d94785d8k.htm   iXBRL 8-K 32649
2 EX-99.1 d94785dex991.htm EX-99.1 7845
6 GRAPHIC g94785111.jpg GRAPHIC 18945
  Complete submission text file 0001193125-20-266787.txt   198704

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA oyst-20201008.xsd EX-101.SCH 3072
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE oyst-20201008_lab.xml EX-101.LAB 18887
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE oyst-20201008_pre.xml EX-101.PRE 11861
7 EXTRACTED XBRL INSTANCE DOCUMENT d94785d8k_htm.xml XML 3477
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39112 | Film No.: 201232107
SIC: 2836 Biological Products, (No Diagnostic Substances)